Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYNORAL vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Contraception (prevention of pregnancy),Endometriosis (off-label use for pain management),Dysfunctional uterine bleeding (off-label),Menstrual suppression (off-label),Hormone replacement therapy component (off-label)
Prevention of pregnancy
50 mg orally three times daily
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life: 12–15 hours (11.2 ± 2.6 h in young adults; 14.8 ± 3.9 h in elderly), requiring once-daily dosing for steady-state within 4–7 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes, forming conjugated metabolites (glucuronides and sulfates) that are excreted renally and fecally.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: ~50% as unchanged drug; ~20% as glucuronide conjugates. Biliary/fecal: ~30% (including enterohepatic recirculation).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
97–99% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.8–1.0 L/kg (indicating extensive extravascular distribution, with significant tissue binding).
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 65–75% (due to first-pass hepatic metabolism; Tmax 2–4 hours).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR 30-50 m L/min: 50 mg twice daily; GFR 15-29 m L/min: 50 mg once daily; GFR <15 m L/min: not recommended
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh class A: no adjustment; class B: 50 mg twice daily; class C: not recommended
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
2 mg/kg/dose orally three times daily; maximum 50 mg per dose
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Initiate at 25 mg twice daily; titrate slowly based on tolerance and renal function
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
LYNORAL carries a boxed warning for increased risk of thromboembolic disorders, including deep vein thrombosis and pulmonary embolism, especially in women with predisposing factors. Use is contraindicated in women with a history of or active thromboembolic disease.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thromboembolic risk: Discontinue if signs of thrombosis occur.,Bone mineral density loss: Long-term use may decrease BMD; consider calcium/vitamin D supplementation.,Hepatic impairment: Use with caution in patients with liver disease; monitor liver function.,Breakthrough bleeding: May occur, especially in the first months of use.,Depression: Monitor for mood changes; discontinue if severe depression develops.,Cardiovascular effects: May increase risk of hypertension and lipid profile changes.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Active or history of thromboembolic disorders (e.g., DVT, PE),Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Current or history of breast cancer (hormone-sensitive),Severe hepatic impairment or liver tumors,Hypersensitivity to LYNNORAL or any component
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Grapefruit juice may increase ethinylestradiol levels by inhibiting CYP3A4. Avoid excessive grapefruit consumption. St. John's Wort decreases effectiveness. No other significant food interactions.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Lynoral (ethinyl estradiol) is contraindicated in pregnancy due to significant teratogenic risk. First trimester exposure increases risk of cardiovascular defects, neural tube defects, and limb reduction anomalies. Second and third trimester exposure may cause fetal feminization in males, urogenital abnormalities, and potential long-term reproductive tract effects. Use only after confirmed absence of pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Ethinyl estradiol is excreted into breast milk with an M/P ratio of approximately 0.37 to 0.50. It may reduce milk production and composition, and expose the infant to estrogenic effects. Use during lactation is generally not recommended; alternative contraception is preferred.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Lynoral is contraindicated in pregnancy; no dose adjustments are applicable. Pharmacokinetic changes such as increased clearance and volume of distribution occur in pregnancy, but the drug should not be used. If inadvertent exposure occurs, immediate discontinuation is required.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Lynoral (ethinylestradiol) is a potent estrogen used primarily in oral contraceptives and hormone therapy. Monitor for thromboembolic events, especially in smokers over 35. Prescribe the lowest effective dose. Assess liver function periodically due to hepatic metabolism. Use with caution in patients with migraine with aura, hypertension, or history of cholestasis. Discontinue 4 weeks prior to elective surgery to reduce thrombotic risk.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take at the same time daily to maintain consistent hormone levels.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially over age 35.,Report symptoms of blood clots: leg pain/swelling, sudden chest pain, difficulty breathing, or vision changes.,May cause nausea; taking with food can help.,Antibiotics (e.g., rifampin) and certain anticonvulsants may reduce effectiveness; use additional contraception.,Do not use during pregnancy; if pregnancy is suspected, discontinue and consult doctor.,Regular blood pressure monitoring is recommended.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYNORAL vs ALYACEN 7/7/7, answered by our medical review team.
LYNORAL is a Oral contraceptive that works by LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYNORAL and ALYACEN 7/7/7 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYNORAL is: 50 mg orally three times daily. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYNORAL and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYNORAL is classified as Category C. Lynoral (ethinyl estradiol) is contraindicated in pregnancy due to significant teratogenic risk. First trimester exposure increases risk of cardiovascular defects, neural tube defe. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.